logo image

ADAGRASIB

ADAGRASIB

Tablets

"KRAZATI (adagrasib) is an irreversible inhibitor of KRAS G12C and belongs to the RAS GTPase family. KRAZATI (adagrasib) tablets for oral administration contain 200 mg of adagrasib. The following are inactive ingredients: colloidal silicon dioxide, crospovidone, magnesium stearate (vegetable sourced), mannitol, and microcrystalline cellulose. The tablet film coating contains hypromellose, maltodextrin, medium chain triglycerides (vegetable sourced), polydextrose, talc, and titanium dioxide. "
KRAZATI (adagrasib) Tablets: 200 mg.
Recommended dosage: 600 mg orally twice daily.
KRAZATI (adagrasib) is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.

Contact Us

Established in New Delhi, India in 2020, ImpoMed Healthcare has grown over the years from a new start up to one of the Most Preferred Company for Facilitation of the Imported Drugs-Only USFDA/European FDA Approved.

Quick Links

Diseases

Corporate Office